Европска Унија - Летонски - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexamethasone - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex ir indicēts, lai ārstētu pieaugušo pacientu, kuriem makulas tūska, kam seko vai nu filiāle tīklenes-vēnu oklūzija (brvo) vai centrālās tīklenes-vēnu oklūzija (crvo). ozurdex ir norādīts ārstēšanai pieaugušiem pacientiem ar iekaisumu aizmugurējā segmenta acu iepazīstinot kā noninfectious uveīta. ozurdex ir norādīts ārstēšanai pieaugušiem pacientiem ar redzes traucējumiem, jo diabētiskā makulas tūska (dme), kas ir pseudophakic vai kuri uzskatāmi par pietiekami atsaucīgas, vai derīgi, kas nav kortikosteroīdu terapija.

Летонија - Летонски - Zāļu valsts aģentūra

abbvie ltd., united kingdom - izoflurāns - inhalācijas tvaiki, šķidrums - 99,9% w/w

Летонија - Летонски - Zāļu valsts aģentūra

abbvie, sia, latvia - dezoksiholskābe - Šķīdums injekcijām - 10 mg/ml

Летонија - Летонски - Zāļu valsts aģentūra

viatris healthcare limited, ireland - ibuprofēns - putojošās granulas - 600 mg

Летонија - Летонски - Zāļu valsts aģentūra

viatris healthcare limited, ireland - ibuprofēns - putojošās granulas - 400 mg

Европска Унија - Летонски - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakteriālas līdzekļi sistēmiskai lietošanai, - acu bakteriālas ādas un ādas struktūras infekcijas (absssi) ārstēšana pieaugušajiem.

Летонија - Летонски - Zāļu valsts aģentūra

abbvie s.r.o., czech republic - izoflurāns - inhalācijas tvaiki, šķidrums - 99,9% w/w

Летонија - Летонски - Zāļu valsts aģentūra

abbvie, sia, latvia - brimonidini tartras, timololum - acu pilieni, šķīdums - 2 mg/5 mg/ml

Летонија - Летонски - Zāļu valsts aģentūra

abbvie, sia, latvia - botulīna toksīns, a tips - pulveris injekciju šķīduma pagatavošanai

Европска Унија - Летонски - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.